Please assess the completion status of the following clinical trial:

Trial Title: NPC-06 to Acute Pain in Herpes Zoster

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. 20 years old or over at the time of informed consent.~2. Both genders.~3. Patients who have acute rash (either erythema or papule or bulla or pustule, or more), except who have crust more than 20% of entire rash at just before the time of the first administration.~4. Patients who are administrated antiviral drug for herpes zoster at the time of the first administration.~5. Patients who are administrated non-opioid analgesics(acetaminophen, NSAIDs) for herpes zoster at the time of the first administration.~6. Patients who the NRS score at the time of below evaluation point is higher than 4.~   * 120 minutes before the start of infusion.~  * Just before the start of infusion.~7. Patients who the therapeutic effect of non-opioid analgesics for herpes zoster has been insufficient.~8. Patients who can admit to hospital for the all assessment duration from first administration until next day (including hospitalized patient).~9. Patients or his/her guardian who give a written informed consent in understanding and willingness after having received enough explanation regarding the study participation.~Exclusion Criteria:~1. Patients who cannot evaluate NRS by themselves.~2. Patients who are suspected to intracranial pressure increase.~3. Patients who have epilepsy, serious psychiatric or serious neurological disease (i. e. dementia, Parkinson disease and schizophrenic disorder) or consciousness disorder.~4. Patients who have malignant tumors (except for patients who have no signs of recurrence under treatment) or patients who are under treatment for HIV or patients who are receiving immunosuppressant.~5. Patients who have complicated idiopathic trigeminal neuralgia.~6. Patients who have other serious pain which may affect the evaluation of acute herpetic pain.~7. Patients who are receiving opioids or steroids(systemic).~8. Patients who have sinus bradycardia or serious disturbance of conduction system.~9. Patients who have history of hypersensitivity against hydantoin compound.~10. Patients who are receiving tadalafil (for pulmonary hypertension), rilpivirine, asunaprevir, daclatasvir, vaniprevir, macitentan or sofosbuvir.~11. Patients who are receiving medications for neuropathic pain, antidepressants, antiarrhythmic drugs, N-methyl-D-aspartate receptor antagonists, muscle relaxants, local anesthetics, an extract from inflammatory rabbit skin inoculated by vaccinia virus, Chinese herbal medications for analgesia, vitamin B12.~12. Patients who are receiving amenamevir.~13. Patients who have meningitis or meningeal irritation signs.~14. Patients who have complications such as serious heart disease, hepatic function disorder or renal function disorder which severity are considered by investigator as grade 3 or more severe with reference to ''Concerning classification criteria for seriousness of adverse drug reactions of medical agents'' .~15. Patients who are receiving fosphenytoin, phenytoin or ethotoin and combination drug including these or have taken these drugs as adjuvant therapy for pain .

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- NPC-06 (high dose) (Type: EXPERIMENTAL): Infuse diluted NPC-06 18mg/kg solution with 3 to 4 times volume of saline. Administarate NPC-06 gradually (slowly) over 18 minutes.
- NPC-06 (low dose) (Type: EXPERIMENTAL): Infuse diluted NPC-06 12mg/kg solution with 3 to 4 times volume of saline. Administarate NPC-06 gradually (slowly) over 12 minutes
- NPC-06 (placebo) (Type: PLACEBO_COMPARATOR): Infuse NPC-06 (placebo) over 12 minutes or 18 minutes

Based on this trial design, predict the completion outcome and termination type (if applicable).